Cour Pharmaceuticals Raises $105M to Transform Autoimmune Treatment

Cour Pharmaceuticals Secures $105 Million in Funding for Groundbreaking Autoimmune Disease Treatments

Biotech firm Cour Pharmaceuticals has successfully raised $105 million in Series A financing, a major milestone in its efforts to develop revolutionary treatments for autoimmune diseases. Lumira Ventures and Alpha Wave Ventures co-led this funding round, which included participation from notable investors such as Roche Venture Fund, Pfizer, Bristol Myers Squibb, Angelini Ventures, and JDRF T1D Fund.